VC-01

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future

/
VC-01-post-implant-final1-e1503703572933, viacyte

It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on […]

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future Read More »

Diabetes Stem Cell Milestone: ViaCyte Transplants 1st Patient

/ / 4 Comments
viacyte-encaptra

Chalk up another exciting development for the stem cell and regenerative medicine field in 2014 related to diabetes. It’s been a huge year. (Update: read my Fall 2019 interview with ViaCyte here.) For the first time ever, an ES cell-based device has been transplanted into a diabetic patient. ViaCyte working together with Dr. Robert Henry

Diabetes Stem Cell Milestone: ViaCyte Transplants 1st Patient Read More »

Subscribe to Our Newsletter

Be the first to know about the latest developments in stem cell and regenerative medicine research.